DIA 2021 Global Annual Meeting

Session Chair(s)

The Parallel Scientific Advice (PSA) procedure is a process for EMA and FDA to concurrently exchange with sponsors their views on scientific issues during the development phase of new medicinal products (i.e., new human drugs and biologics). Such interactions are expected to increase dialogue between the two agencies and sponsors from the beginning of the lifecycle of a new product, provide a deeper understanding of the bases of regulatory decisions, optimize product development, and avoid unnecessary testing replication or unnecessary diverse testing methodologies. This session will be led by EMA and FDA PSA participants and program managers, as well as a participant offering the industry perspective. Attendees will better understand the PSA procedure, how to apply, and expectations on outcomes.

Learning Objective : Explain the Parallel Scientific Advice (PSA) procedure framework and timelines; Identify best candidates for PSA and best practices for request letters; review statistics on utilization of the PSA procedure; Describe Industry’s and each Agency’s unique perspective and contribution to PSA.

Speaker(s)